These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 19626585)

  • 21. [Relationship between nucleotide excision repair gene ERCC1 and resistance to cisplatin in ovarian cancer].
    Liu GY; Qu QX; Mi RR; Qi J
    Zhonghua Zhong Liu Za Zhi; 2008 Mar; 30(3):184-7. PubMed ID: 18756932
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Role of neurofilament light polypeptide in head and neck cancer chemoresistance.
    Chen B; Chen J; House MG; Cullen KJ; Nephew KP; Guo Z
    Mol Cancer Res; 2012 Mar; 10(3):305-15. PubMed ID: 22246235
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CpG island hypermethylation of the DNA repair enzyme methyltransferase predicts response to temozolomide in primary gliomas.
    Paz MF; Yaya-Tur R; Rojas-Marcos I; Reynes G; Pollan M; Aguirre-Cruz L; García-Lopez JL; Piquer J; Safont MJ; Balaña C; Sanchez-Cespedes M; García-Villanueva M; Arribas L; Esteller M
    Clin Cancer Res; 2004 Aug; 10(15):4933-8. PubMed ID: 15297393
    [TBL] [Abstract][Full Text] [Related]  

  • 24. DNA methylation-mediated caspase-8 downregulation is associated with anti-apoptotic activity and human malignant glioma grade.
    Teng Y; Dong YC; Liu Z; Zou Y; Xie H; Zhao Y; Su J; Cao F; Jin H; Ren H
    Int J Mol Med; 2017 Mar; 39(3):725-733. PubMed ID: 28204824
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Drug sensitivity prediction by CpG island methylation profile in the NCI-60 cancer cell line panel.
    Shen L; Kondo Y; Ahmed S; Boumber Y; Konishi K; Guo Y; Chen X; Vilaythong JN; Issa JP
    Cancer Res; 2007 Dec; 67(23):11335-43. PubMed ID: 18056460
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Excision repair cross-complementing group 1 may predict the efficacy of chemoradiation therapy for muscle-invasive bladder cancer.
    Kawashima A; Nakayama M; Kakuta Y; Abe T; Hatano K; Mukai M; Nagahara A; Nakai Y; Oka D; Takayama H; Yoshioka T; Hoshida Y; Itatani H; Nishimura K; Nonomura N
    Clin Cancer Res; 2011 Apr; 17(8):2561-9. PubMed ID: 21177407
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer.
    Cobo M; Isla D; Massuti B; Montes A; Sanchez JM; Provencio M; Viñolas N; Paz-Ares L; Lopez-Vivanco G; Muñoz MA; Felip E; Alberola V; Camps C; Domine M; Sanchez JJ; Sanchez-Ronco M; Danenberg K; Taron M; Gandara D; Rosell R
    J Clin Oncol; 2007 Jul; 25(19):2747-54. PubMed ID: 17602080
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Predicting clinical chemo-sensitivity of primary ovarian cancer using adenosine triphosphate-tumor chemosensitivity assay combined with detection of drug resistance genes].
    Zhao D; Zhang W; Li XG; Wang XB; Zhang LF; Li M; Li YF; Tian HM; Song PP; Liu J; Chang QY; Wu LY
    Zhonghua Fu Chan Ke Za Zhi; 2011 Mar; 46(3):193-8. PubMed ID: 21575453
    [TBL] [Abstract][Full Text] [Related]  

  • 29. TP53 promoter methylation in human gliomas.
    Amatya VJ; Naumann U; Weller M; Ohgaki H
    Acta Neuropathol; 2005 Aug; 110(2):178-84. PubMed ID: 16025287
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Promoter methylation and silencing of the tissue factor pathway inhibitor-2 (TFPI-2), a gene encoding an inhibitor of matrix metalloproteinases in human glioma cells.
    Konduri SD; Srivenugopal KS; Yanamandra N; Dinh DH; Olivero WC; Gujrati M; Foster DC; Kisiel W; Ali-Osman F; Kondraganti S; Lakka SS; Rao JS
    Oncogene; 2003 Jul; 22(29):4509-16. PubMed ID: 12881707
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lentivirus-Mediated RNAi silencing targeting ERCC1 reverses cisplatin resistance in cisplatin-resistant ovarian carcinoma cell line.
    Du P; Zhang X; Liu H; Chen L
    DNA Cell Biol; 2015 Jul; 34(7):497-502. PubMed ID: 25941922
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Careful exclusion of non-neoplastic brain components is required for an appropriate evaluation of O6-methylguanine-DNA methyltransferase status in glioma: relationship between immunohistochemistry and methylation analysis.
    Sasai K; Nodagashira M; Nishihara H; Aoyanagi E; Wang L; Katoh M; Murata J; Ozaki Y; Ito T; Fujimoto S; Kaneko S; Nagashima K; Tanaka S
    Am J Surg Pathol; 2008 Aug; 32(8):1220-7. PubMed ID: 18580490
    [TBL] [Abstract][Full Text] [Related]  

  • 33. An Epigenetic Mechanism of High Gdnf Transcription in Glioma Cells Revealed by Specific Sequence Methylation.
    Zhang BL; Liu J; Lei Y; Xiong Y; Li H; Lin X; Yao RQ; Gao DS
    Mol Neurobiol; 2016 Sep; 53(7):4352-62. PubMed ID: 26232065
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Relationship between TYMS and ERCC1 mRNA expression and in vitro chemosensitivity in colorectal cancer.
    Cho YB; Chung HJ; Lee WY; Choi SH; Kim HC; Yun SH; Chun HK
    Anticancer Res; 2011 Nov; 31(11):3843-9. PubMed ID: 22110208
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Excision repair cross-complementation group 1 (ERCC1) in platinum-based treatment of non-small cell lung cancer with special emphasis on carboplatin: a review of current literature.
    Vilmar A; Sørensen JB
    Lung Cancer; 2009 May; 64(2):131-9. PubMed ID: 18804893
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [ERCC1 as a Marker of Ovarian Cancer Resistance to Platinum Drugs].
    Bogush TA; Popova AS; Dudko EA; Bogush EA; Tyulyandina AS; Tyulyandin SA; Davydov MI
    Antibiot Khimioter; 2015; 60(3-4):42-50. PubMed ID: 26415382
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Transcriptional expression of glioma chemotherapy drugs associated marker molecules in gliomas and normal brain tissues.
    Zhao Y; Xue Y; Zhang Q; Wang K; Yin J; Lou M
    Cancer Biomark; 2013; 13(1):59-66. PubMed ID: 23736022
    [TBL] [Abstract][Full Text] [Related]  

  • 38. ERCC1 expression as a molecular marker of cisplatin resistance in human cervical tumor cells.
    Britten RA; Liu D; Tessier A; Hutchison MJ; Murray D
    Int J Cancer; 2000 Sep; 89(5):453-7. PubMed ID: 11008208
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hypermethylation of the RASSF1A gene in gliomas.
    Gao Y; Guan M; Su B; Liu W; Xu M; Lu Y
    Clin Chim Acta; 2004 Nov; 349(1-2):173-9. PubMed ID: 15469871
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tanshinone IIA acts via p38 MAPK to induce apoptosis and the down-regulation of ERCC1 and lung-resistance protein in cisplatin-resistant ovarian cancer cells.
    Jiao JW; Wen F
    Oncol Rep; 2011 Mar; 25(3):781-8. PubMed ID: 21165580
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.